P51 / Research station
Home / Research Library / TB-500 Research: Identity & Thymosin Beta-4 Distinctions
Compound research profile

TB-500 Research: Identity & Thymosin Beta-4 Distinctions

A source-linked look at TB-500 naming, a characterized thymosin beta-4 fragment, and why sequence confirmation comes before comparing studies.

Peptides51 · Published October 9, 2026 · Source-linked educational overview

Why identity comes first

A 2012 analytical study identified an N-terminal acetylated 17–23 fragment of human thymosin beta-4, Ac-LKKTETQ, in a product described as TB-500. That finding describes the tested material, not every item subsequently sold under that name.

What the cited paper contributes

The researchers used chromatography and high-resolution mass spectrometry to characterize the fragment. The contribution is analytical identification. It should not be repurposed as evidence for the safety or effectiveness of an unrelated product.

TB-500 is not a substitute for a sequence

Before comparing results, establish whether a paper concerns full-length thymosin beta-4, the characterized fragment, or another material. Similar naming does not demonstrate chemical equivalence.

A documentation checklist

Request the stated sequence, modifications, expected mass, batch identifier and supporting identity evidence. Compare these with the actual material in the publication before linking a paper to a supplier listing.

Sources & further reading

  1. Esposito et al., 2012 — characterization of the TB-500 fragment
This overview explains research context and evidence limits. It is not a systematic review or medical guidance. No availability, product quality, or equivalence to study materials is implied. Follow the original source for methods and limitations.

Continue reading

Explore all research guides →

Browse the compound directory →

P51 / Evidence tracker

FDA approval & clinical-trial status

Sources checked 2026-10-10 (UTC). Status describes registry records and named drug products.

FDA / United States

No FDA approval record located

The checked Drugs@FDA ingredient searches did not locate an approval record. This is a database search result, not an exhaustive regulatory determination; compounding eligibility is a separate question.

    FDA database and coverage ↗
    ClinicalTrials.gov

    Active study records reported

    1 active · 0 planned · 0 completed · 1 matching records

    Counts include matching drug or biological interventions in ClinicalTrials.gov. Biomarker-only studies and related compounds are excluded. Registration and a reported phase do not establish safety, efficacy, FDA approval, or that a trial is taking place as described. Check each record and its update date.

    Search the trial registry ↗
    View matching trial records (1)
    Publication archive

    Articles associated with TB-500

    Indexed publications mentioning this compound in their title or abstract, newest first. Follow the original papers for findings and limitations; preprints are labeled.

    Open full source search ↗

    35 indexed matches. Sources checked 2026-10-10 (UTC).

    Search coverage is limited to Europe PMC. Related names, formulations, and study models may differ from listed research materials. A paper mentioning a compound is not necessarily a clinical trial or evidence of effectiveness.